Biomea Fusion, Inc.
Business
Biomea Fusion is a clinical-stage pharmaceutical company developing oral, small-molecule drugs for diabetes, obesity, and metabolic diseases. The company's pipeline comprises icovamenib, a covalent menin inhibitor in Phase II trials for type 1 and type 2 diabetes and obesity, and BMF-650, a next-generation oral GLP-1 receptor agonist in Phase I for obesity. The company retains full worldwide development and commercialization rights to its candidates. Biomea operates as a focused organization with integrated clinical development and regulatory functions.
Summary from 10-K filed 2026-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 62 | 118 | 103 | 63 | 28 | |
| General and administrative | 19 | 26 | 24 | 21 | 14 | |
| Impairment of long-lived assets | 2 | 0 | 0 | — | — | |
| Total operating expenses | 84 | 144 | 126 | 84 | 42 | |
| Loss from operations | −84 | −144 | −126 | −84 | −42 | |
| Change in fair value of common warrant liability | 20 | 0 | 0 | — | — | |
| Interest and other income, net | 2 | 6 | 9 | 2 | 100,000 | |
| Net loss | −62 | −138 | −117 | −82 | −42 | |
| Unrealized gain on investments, net | — | — | 1,000 | 9,000 | −10,000 | |
| Comprehensive loss | −62 | −138 | −117 | −82 | −42 | |
| Net loss per common share, basic | −1.18 | −3.83 | −3.44 | −2.8 | −1.74 | |
| Net loss per common share, diluted | −1.18 | −3.83 | −3.44 | −2.8 | −1.74 | |
| Weighted-average number of common shares used to compute basic net loss per common share | 52 | 36 | 34 | 29 | 24 | |
| Weighted-average number of common shares used to compute diluted net loss per common share | 52 | 36 | 34 | 29 | 24 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 56 | 58 | 177 | 112 | 146 | |
| Prepaid expenses and other current assets | 2 | 10 | 2 | 5 | 3 | |
| Total current assets | 58 | 68 | 179 | 118 | 177 | |
| Property and equipment, net | 153,000 | 4 | 5 | 6 | 3 | |
| Restricted cash | 369,000 | 369,000 | 370,000 | 351,000 | 351,000 | |
| Other non-current assets | 0 | 619,000 | 6 | 3 | 1 | |
| Operating lease right-of-use assets | 0 | 7 | 10 | 2 | 3 | |
| Total assets | 59 | 80 | 200 | 129 | 186 | |
| Accounts payable | 3 | 13 | 7 | 7 | 1 | |
| Accrued expenses and other current liabilities | 6 | 7 | 14 | 12 | 3 | |
| Operating lease liabilities, current | 1 | 2 | 2 | 618,000 | 565,000 | |
| Total current liabilities | 11 | 22 | 23 | 19 | 5 | |
| Operating lease liabilities, non-current | 128,000 | 7 | 8 | 2 | 2 | |
| Warrant liability, non-current | 18 | 0 | — | — | — | |
| Total liabilities | 29 | 28 | 31 | 21 | 7 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — | — | — | — | |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 72,299,440 and 36,310,713 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 7,000 | 4,000 | 4,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 479 | 439 | 418 | 240 | 229 | |
| Accumulated deficit | −449 | −387 | −249 | −132 | −50 | |
| Total stockholders' equity | 30 | 52 | 169 | 109 | 179 | |
| Total liabilities and stockholders' equity | 59 | 80 | 200 | 129 | 186 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −62 | −138 | −117 | −82 | −42 | |
| Depreciation expense | 1 | 2 | 2 | 700,000 | 200,000 | |
| Non-cash operating lease expense | 2 | 3 | 3 | 571,000 | 704,000 | |
| Stock-based compensation expense | 10 | 19 | 14 | 10 | 6 | |
| Net amortization of premiums and accretion of discounts on investments | — | — | 1,000 | 144,000 | 516,000 | |
| Prepaid expenses and other current assets | 8 | −8 | 2 | −2 | −3 | |
| Other non-current assets | 619,000 | 5 | −2 | — | — | |
| Accounts payable | −10 | 6 | 3 | 3 | 640,000 | |
| Accrued expenses and other current liabilities | −255,000 | −7 | 2 | 9 | 2 | |
| Operating lease liabilities | −2 | −2 | −2 | −565,000 | −589,000 | |
| Net cash used in operating activities | −70 | −120 | −97 | −62 | −35 | |
| Purchase of property and equipment | — | −362,000 | −3 | −1 | −3 | |
| Maturities of investments | — | — | 1 | 28 | 8 | |
| Net cash (used in) provided by investing activities | — | −362,000 | −2 | 27 | −33 | |
| Proceeds from issuance of common stock under at the market equity offering program, net of offering costs | 5 | — | 162 | — | — | |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants, net of offering costs | 63 | — | 162 | — | — | |
| Proceeds from stock options exercised and purchases under the employee stock purchase plan | 159,000 | 2 | 2 | 1 | 468,000 | |
| Net cash provided by financing activities | 68 | 2 | 164 | 1 | 153 | |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | −2 | −119 | 65 | −34 | 84 | |
| Acquisition of operating lease right-of-use assets | — | — | 6 | — | 3 | |
| Acquisition of property and equipment in accounts payable and accrued liabilities | — | 7,000 | — | 3 | — | |
| Remeasurement of operating lease right-of-use assets and lease liability | 5 | — | 6 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Biomea Fusion, Inc.'s CIK number?
Biomea Fusion, Inc.'s SEC CIK number is 0001840439 (1840439). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Biomea Fusion, Inc.'s SEC filings?
All of Biomea Fusion, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Biomea Fusion, Inc. last report earnings?
Biomea Fusion, Inc. (BMEA) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-217037). This is Biomea Fusion, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Biomea Fusion, Inc.'s most recent earnings 8-K?
Biomea Fusion, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-217037. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Biomea Fusion, Inc.'s latest earnings 8-K →
Look up any company's CIK number →